Nimbus Discovery Announces Agreement With Shire plc to Co-Develop Therapies for Rare Diseases
5/8/2013 10:58:44 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Discovery, LLC, a biotechnology company discovering novel medicines against exciting but previously inaccessible disease targets, today announced a co-development agreement with Shire plc focused on small molecule treatments for several rare genetic diseases known as lysosomal storage disorders (LSDs). The goal of the collaboration is to utilize the Nimbus breakthrough computational chemistry approach to discover and develop novel, disease-altering therapies. Many LSDs remain untreated because of challenges in creating drugs that can effectively reach the disease site. The significant potential of this partnership is the development of the first small molecule agents designed to penetrate inaccessible tissues while offering the convenience of an orally-administered pill.
Help employers find you! Check out all the jobs and post your resume.
comments powered by